TFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

TFG Asset Management GP Ltd lowered its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 67.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 200,000 shares of the company's stock after selling 414,117 shares during the quarter. Tarsus Pharmaceuticals comprises approximately 2.4% of TFG Asset Management GP Ltd's holdings, making the stock its 15th largest holding. TFG Asset Management GP Ltd owned 0.52% of Tarsus Pharmaceuticals worth $11,074,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TARS. Crowley Wealth Management Inc. bought a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $53,000. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $166,000. Finally, HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $207,000. Institutional investors own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TARS. Barclays cut their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group raised their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research note on Monday, May 5th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective for the company in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.17.

Tarsus Pharmaceuticals Stock Performance

Shares of Tarsus Pharmaceuticals stock traded up $0.17 during trading on Wednesday, reaching $42.05. The company's stock had a trading volume of 748,538 shares, compared to its average volume of 702,651. The business's 50-day moving average price is $47.43 and its 200-day moving average price is $49.04. The firm has a market cap of $1.77 billion, a PE ratio of -11.04 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the transaction, the general counsel now owns 58,057 shares of the company's stock, valued at $2,687,458.53. This represents a 5.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Dianne C. Whitfield sold 2,315 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares of the company's stock, valued at $2,349,263.79. This represents a 4.36% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is currently owned by corporate insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.